GSK and Pfizer to merge consumer health businesses

GlaxoSmithKline (GSK) and Pfizer are to combine their consumer health businesses into a single entity with combined global sales of £9.8 billion. GSK will have a 68 per cent controlling equity stake in the new joint venture and Pfizer 32 per cent.

The move will bring together GSK’s Panadol, Voltarol and Sensodyne brands with Pfizer’s Advil, Centrum and Caltrate products in a new company, GSK Consumer Healthcare.

The joint venture will be a category leader in pain relief, respiratory, vitamin and mineral supplements, digestive health, skin health and therapeutic oral health, the companies say, with a global OTC market share of 7.3 per cent, making it the clear number one player.

GSK intends to create two new UK-based businesses, one focusing on pharmaceuticals and vaccines, the other on consumer healthcare, within three years of the deal being approved by regulators and shareholders.

Recommended

Well data breach: PDA progressing comp claim

Pharmacies give out free vape kits in new trial




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.